With XR-Series you can optimise your haematology workflow automation

Our EDTA tube handling devices improve workflow and operational efficiency by automating a variety of manual steps, thereby relieving the lab staff significantly. 

The new BT-50 innovates haematology automation. It is a ‘cool’ multi-talent that reaches way beyond barcode reading of tubes. One example is the scheduled automated start-up of the automation line and shutdown of individual modules or the whole line. 

Finding instead of searching – the TS-10 helps to standardise and optimise complex sample workflows. Its key competences are post-analytical and on-demand pre-analytical sorting of EDTA tubes for all kinds of criteria: storage, reflex testing, special orders, or rack optimisation. 

Optimise your smear workflow with integrated smear-making, staining and digital imaging to ensure high-quality morphology results, every time. With extensive networking capabilities, our digital imaging portfolio allows you to share morphology expertise within your organisation or across multiple sites, on demand from anywhere at any time.

Discover the benefits each solution offers. 

With the integration possibility of specific non-XR analysers in your XR automation line, you can have your EDTA blood samples transferred fully automatically for subsequent testing. Samples with open orders for HbA1c and/or ESR measurement are moved to the dedicated analysers once blood count analysis has been finished. This shortens TAT, increases walk-away time and consolidates analysis orders to a single EDTA tube per patient.

Discover each analyser’s capabilities.

Beyond tube handling components, smear workflow devices and different analysers, there are further beneficial options that can be added to your XR automation solution. 

For high workloads, it can save a significant amount of time and effort for your staff to have high-volume reagents directly prepared from a concentrate and dispensed into the system rather than exchanging many individual containers throughout the day. 

This clever device helps you fit your automation line to your lab’s space. Use one or two units to set up your favoured layout – always space-conscious yet comfortable to work at. 

Your XR automation line can be connected to total lab automation solutions. Contact your local Sysmex representative to find the best solution for your lab’s individual situation. 

Pre-analytical rules 

With this rule set in place, the system automatically checks each sample according to the set pre-analysis rules, plus it checks the patient’s history and special requirements the sample may have. This makes for a smooth workflow with optimised sample processing. 

This set covers rules for assessing the reliability of results and so helps to provide accurate and technically sound analysis results. In addition, it manages the automatic reflex measurements of analytical alternatives. This package is the basic prerequisite for any subsequent validation steps. 

Based on the GFHC recommended guidelines [1], the optional extra Biomedical Validation rule set offers a standardised workflow for managing abnormal samples so you can focus on the right results at the right time [2]. 

Alternatively, you can use this rule set as a base to create a bespoke rule set package defined together with our expert workflow analysts. 

[1] Genevieve F et al. (2014): Smear microscopy revision: propositions by the GFHC, Feuillets de Biologie (Vol LVI N° 317). Free download of the French and English version: http://www.gfhc.fr/fr/documents/page-2/ 

[2] Cornet E et al. (2016): Evaluation and optimization of the extended information process unit (E-IPU) validation module integrating the sysmex flag systems and the recommendations of the Frenchspeaking cellular hematology group (GFHC). Scand J Clin Lab Invest. 76(6):465–71. 

This rule set offers technical validation and interpretation support for body fluid results. Different criteria apply depending on the sample category, i.e., CSF and all others. During validation, you can add information on macroscopic sample characteristics. The rules provide indications of interferences and recommendations for actions to be performed, such as chamber counts or cytospin preparations. This contributes to the overall safety level and confidence in the results of such vulnerable samples. 

CBC-O* – an optimisation to resolve cases of an increased MCHC* 

Confidently handle samples with an increased MCHC: The optional CBC-O add-on in the Extended IPU supports you in identifying the cause and suggests reporting alternative parameters from other channels not affected by potential interferences – all without manual intervention or ordering additional tests.  

Berda-Haddad Y et al. (2017): Increased mean corpuscular haemoglobin concentration: artefact or pathological condition? Int J Lab Hematol. 39(1): 32. 

TWO ensures your XR analysers use the best available PLT count method for abnormal samples and ones with interferences. Whenever PLT-F analysis is performed, the IPF parameter may aid in the decision-making process that leads to a final diagnosis.

This add-on operates in combination with CBC-O. It supports an optimised detection and sample workflow for suspected hereditary RBC diseases. When ‘rare’ becomes increasingly frequent, RWO will be there to support your lab effectively. 

Nivaggioni V et al. (2020): Use of Sysmex XN-10 red blood cell parameters for screening of hereditary red blood cell diseases and iron deficiency anaemia. Int J Lab Hematol. 42(6): 697. 

Nivaggioni V et al. (2022): Detection of Southern Asian Ovalocytosis with Sysmex XN-10: A complement to the decision tree previously described. Int J Hematol. 44(2): e84. 

Where do you set your MONO# cut-off for smears? Balancing the burden of smear workload with the risk of missing critical samples is not easy. MWO optimises the detection of CMML samples while excluding reactive monocytosis. 

Schillinger F et al. (2017): A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XN analyzers in routine laboratory practice. Scand J Clin Lab Invest. 78(3): 159. 

* For research use only